Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.49 |
| ▸ | ENPEP | Q07075 | 7/20 | 0.48 |
| ▸ | GNPAT | O15228 | 1/20 | 0.47 |
| ▸ | ECE1 | P42892 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7825934 | 1.00 | MME (0.49) | MMEENPEPGNPATECE1CA2 | |
| SCHEMBL8648570 | 1.00 | MME (0.49) | MMEENPEPGNPATECE1CA2 | |
| SCHEMBL30355295 | 1.00 | MME (0.49) | MMEENPEPGNPATECE1CA2 | |
| SCHEMBL8650914 | 1.00 | MME (0.49) | MMEENPEPGNPATECE1CA2 | |
| SCHEMBL30798028 | 0.96 | GNPAT (0.53) | MMEENPEPGNPATECE1CA2 | |
| SCHEMBL30798044 | 0.96 | GNPAT (0.53) | MMEENPEPGNPATECE1CA2 | |
| SCHEMBL29384981 | 0.93 | ENPEP (0.44) | MMEENPEPGNPATECE1CA2 | |
| SCHEMBL30193555 | 0.91 | MME (0.54) | MMEENPEPGNPATECE1NOD1 | |
| SCHEMBL30193189 | 0.91 | MME (0.54) | MMEENPEPGNPATECE1NOD1 | |
| SCHEMBL26222728 | 0.91 | GNPAT (0.46) | MMEENPEPGNPATECE1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4114417-A2 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2023-01-11 | — | — | EP | claimed |
| CN-115427051-A | Therapeutic agents and conjugates thereof | 北京轩义医药科技有限公司 | 2022-12-02 | — | — | CN | claimed |
| US-20220257789-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | EXELIXIS, INC. | 2022-08-18 | — | — | US | claimed |
| EP-3999118-A1 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | Immunesensor Therapeutics, Inc. (US) | 2022-05-25 | — | — | EP | claimed |
| EP-3994150-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | Iconic Therapeutics, Inc. (US) | 2022-05-11 | — | — | EP | claimed |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | NOVARTIS AG (CH) | 2026-05-12 | — | — | US | disclosed |
| US-20260035473-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view | NOVARTIS AG (CH) | 2026-02-05 | — | — | US | disclosed |
| US-20260028420-A1 | ANTI-TUMOR ANTIBODIES | IMMUNOME INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260022193-A1 | METHODS OF TREATMENT USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 | ZYMEWORKS BC INC (CA) | 2026-01-22 | — | — | US | disclosed |
| US-20260014265-A1 | TRIPLE-PAYLOAD ANTIBODY-DRUG CONJUGATES (ADCs) | ARARIS BIOTECH AG (CH) | 2026-01-15 | — | — | US | disclosed |
| EP-4653017-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Tyligand Bioscience (Shanghai) Limited (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250339552-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | ZYMEWORKS BC INC (CA) | 2025-11-06 | — | — | US | disclosed |
| US-20220105198-A1 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | IMMUNESENSOR THERAPEUTICS, INC. | 2022-04-07 | — | — | US | disclosed |
| EP-3976098-A1 | METHODS OF USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 FOR THE TREATMENT OF BILIARY TRACT CANCERS | Zymeworks Inc. (CA) | 2022-04-06 | — | — | EP | disclosed |
| EP-3972993-A1 | VARIANT CD58 DOMAINS AND USES THEREOF | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972634-A2 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972998-A1 | CD19 BINDING MOLECULES AND USES THEREOF | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| US-20220089772-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| CN-114222752-A | Anti-tissue factor antibody-drug conjugates and related methods | 伊科尼克治疗公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114025795-A | Methods of treating biliary tract cancer using bispecific antigen-binding constructs targeting HER2 | 酵活有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014265-A1 | TRIPLE-PAYLOAD ANTIBODY-DRUG CONJUGATES (ADCs) | TOP2A, TOP1, TOP2B | MME 2553/4885ENPEP 883/4885GNPAT 3858/4885 |
| US-20250339552-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | FOLR1, FOLR2, DHFR | MME 4673/4885ENPEP 2089/4885GNPAT 1262/4885 |
| US-20220105198-A1 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | STING1, CGAS, MAVS | MME 3048/4885ENPEP 1569/4885GNPAT 2911/4885 |
| US-20260022193-A1 | METHODS OF TREATMENT USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 | IGSF11, ERBB2, PDCD1LG2 | MME 2116/4885ENPEP 1024/4885GNPAT 4717/4885 |
| US-20220257789-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | F3, F13B, TFPI | MME 302/4885ENPEP 245/4885GNPAT 1327/4885 |
| US-20260035473-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view | BCL9, BRCA1, VCAM1 | MME 3834/4885ENPEP 1840/4885GNPAT 4809/4885 |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | CD2, CD40, CD22 | MME 1942/4885ENPEP 1841/4885GNPAT 2214/4885 |
| US-20220089772-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | MUC1, SIGLEC7, SIGLEC9 | MME 1375/4885ENPEP 236/4885GNPAT 1776/4885 |
| US-20260028420-A1 | ANTI-TUMOR ANTIBODIES | B4GALT1, ST6GAL1, GALNT3 | MME 2133/4885ENPEP 234/4885GNPAT 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.